Related Experiment Video
Updated: Jun 20, 2026
Stimulation of Notch Signaling in Mouse Osteoclast Precursors
Published on: February 28, 2017
Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia
Teresa Palomero1, Adolfo Ferrando
1Department of Pathology, Institute for Cancer Genetics, Columbia University, New York, USA.
Abstract:
The recent identification of activating mutations in NOTCH1 in the majority of T-cell acute lymphoblastic leukemias (T-ALLs) has brought major interest toward targeting the NOTCH signaling pathway in this disease. Small-molecule gamma-secretase inhibitors (GSIs), which block a critical proteolytic step required for NOTCH1 activation, can effectively block the activity of NOTCH1 mutant alleles. However, the clinical development of GSIs has been hampered by their low cytotoxicity against human T-ALL and the development of significant gastrointestinal toxicity derived from the inhibition of NOTCH signaling in the gut. Improved understanding of the oncogenic mechanisms of NOTCH1 and the effects of NOTCH inhibition in leukemic cells and the intestinal epithelium are required for the design of effective anti-NOTCH1 therapies in T-ALL.
Insights
Targeting NOTCH1 in T-cell acute lymphoblastic leukemia (T-ALL) is promising, but gamma-secretase inhibitors show limited efficacy and cause gut toxicity. Further research is needed for better anti-NOTCH1 therapies.
Area of Science:
- Oncology
- Molecular Biology
- Signaling Pathways
Background:
- Activating mutations in NOTCH1 are prevalent in T-cell acute lymphoblastic leukemia (T-ALL).
- The NOTCH signaling pathway is a key target for T-ALL treatment.
- Small-molecule gamma-secretase inhibitors (GSIs) block NOTCH1 activation but have limitations.
Purpose of the Study:
- To investigate the potential of targeting the NOTCH signaling pathway in T-ALL.
- To understand the mechanisms of NOTCH1 oncogenesis in T-ALL.
- To evaluate the efficacy and toxicity of GSIs in T-ALL and the intestinal epithelium.
Main Methods:
- Utilizing small-molecule gamma-secretase inhibitors (GSIs).
- Assessing cytotoxicity against human T-ALL cell lines.
- Analyzing NOTCH signaling inhibition in leukemic cells and intestinal epithelium.
Main Results:
- GSIs can block NOTCH1 mutant alleles.
- GSIs exhibit low cytotoxicity against human T-ALL.
- GSIs cause significant gastrointestinal toxicity due to gut NOTCH inhibition.
Conclusions:
- Targeting NOTCH1 in T-ALL requires further investigation.
- Improved understanding of NOTCH1 oncogenic mechanisms is crucial.
- Development of effective anti-NOTCH1 therapies necessitates addressing GSI limitations and toxicity.
Related Concept Videos
03:14Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
03:14Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...